Journal of Radiation Oncology

, Volume 6, Issue 2, pp 133–141 | Cite as

Recurrent glioblastoma: a single-institution experience with reirradiation and temozolomide

  • Tejinder Kataria
  • Deepak Gupta
  • Ratika Gupta
  • Shikha Goyal
  • Shyam Singh Bisht
  • Trinanjan Basu
  • Ashu Abhishek
  • Kushal Narang
  • Susovan Banerjee
Original Research



Glioblastoma is an aggressive disease with poor prognosis. Outcomes following recurrences are dismal despite the use of multimodality treatment. Surgery is usually not a viable option, and even in those who do undergo surgery, adjuvant radiation therapy with or without concurrent chemotherapy may be viable options depending on several factors such as performance status, disease volume, and time since prior therapy. We intended to assess the efficacy of high precision reirradiation with temozolomide as a salvage modality in patients with recurrent glioblastoma.


Twenty-five patients with recurrent glioblastoma who received reirradiation (with or without concurrent temozolomide) for recurrence at our department between 2010 and 2015 were included in this retrospective analysis. Treatment decisions are taken following recommendations of multidisciplinary tumor board. Treatment details were noted from respective case records. Survival time was calculated using Kaplan-Meier method. Univariate and multivariate analyses were performed using Cox regression analysis.


Eighteen men and seven women with a mean age of 52 years (range, 20–65 years) received reirradiation during the given period. Median Karnofsky Performance Score (KPS) was 70% (range, 40–90). Twelve patients underwent surgery before reirradiation, while 13 patients were deemed inoperable and direct taken for reirradiation. The reirradiation methods included stereotactic radiosurgery (2), hypofractionated stereotactic radiation therapy (15–40 Gy in 3–5 fractions; 14 patients), or conventionally fractionated stereotactic radiation therapy (45–54 Gy in 25–27 fractions; 9 patients). Patients who received conventional fractionated radiation also received concurrent temozolomide at 75 mg/m2. All patients completed the planned course of radiation therapy and also received adjuvant temozolomide. MGMT methylation status was available for 15 patients; 7 had MGMT methylated while 8 had non-methylated tumors.

Median follow-up from recurrence was 12 months (range, 1–47.8 months). Median overall survival (OS) from recurrence was 15.2 months (95% confidence interval [CI], 10–20.33 months). None of the factors analyzed (age, sex, gross tumor volume at time of recurrence, KPS, MGMT, time of recurrence) were significant for outcomes. No grade 3 or above acute or late complications were noted following reirradiation.


Our results suggest that reirradiation with high precision radiotherapy along with temozolomide is an effective option in patients with recurrent glioblastoma.


Recurrent glioblastoma Reirradiation Temozolomide 


Compliance with ethical standards


No funding was received for this study.

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

For this type of study, formal consent specific to the study is not required. However, consent for the planned treatment was taken from each patient at the time of enrolment, with permission to use the anonymised data for research purposes.


  1. 1.
    Amelio D, Amichetti M (2012) Radiation therapy for the treatment of recurrent glioblastoma: an overview. Cancers (Basel). 4(1):257–280CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Amichetti M, Amelio D (2011) A review of role of re-irradiation in recurrent high grade glioma. Cancers (Basel) 3(4):4061–4089CrossRefGoogle Scholar
  3. 3.
    Biswas T, Okunieff P, Schell MC, Smudzin T, Pilcher WH, Bakos RS et al (2009) Stereotactic radiosurgery for glioblastoma: retrospective analysis. Radiat Oncol Lond Engl 4:11CrossRefGoogle Scholar
  4. 4.
    Cabrera AR, Cuneo KC, Desjardins A, Sampson JH, McSherry F, Herndon JE II, Peters KB, Allen K, Hoang JK, Chang Z et al (2013) Concurrent stereotactic radiosurgery and bevacizumab in recurrent malignant gliomas: a prospective trial. Int J Radiat Oncol Biol Phys 86:873–879CrossRefPubMedGoogle Scholar
  5. 5.
    Cassano A, Longo R, Angelelli L, et al. (2001). Temozolomide in first line treatment of recurrent or residual malignant brain tumors. ASCO Proceedings, Annual Meeting, Abstract No. 2058
  6. 6.
    Cho KH, Hall WA, Gerbi BJ, Higgins PD, McGuire WA, Clark HB (1999) Single dose versus fractionated stereotactic radiotherapy for recurrent high-grade gliomas. Int J Radiat Oncol Biol Phys 45(5):1133–1141CrossRefPubMedGoogle Scholar
  7. 7.
    Combs SE, Bischof M, Welzel T et al (2008) Radiochemotherapy with temozolomide as re-irradiation using high precision fractionated stereotactic radiotherapy (FSRT) in patients with recurrent gliomas. J Neuro-Oncol 89(2):205–210CrossRefGoogle Scholar
  8. 8.
    Combs SE, Edler L, Rausch R, Welzel T, Wick W, Debus J (2013) Generation and validation of a prognostic score to predict outcome after re-irradiation of recurrent glioma. Acta Oncol Stockh Swed 52(1):147–152CrossRefGoogle Scholar
  9. 9.
    Conti A, Pontoriero A, Arpa D, et al; Efficacy and toxicity of CyberKnife re-irradiation and “dose dense” temozolomide for recurrent gliomas. Acta Neurochir 2012; 154(2):203–209.Google Scholar
  10. 10.
    Dhermain F, de Crevoisier R, Parker F et al (2004) Role of radiotherapy in recurrent gliomas. Bull Cancer 91(11):883–889PubMedGoogle Scholar
  11. 11.
    Dincoglan F, Beyzadeoglu M, Sager O et al (2015) Management of patients with recurrent glioblastoma using hypofractionated stereotactic radiotherapy. Tumori 101(2):179–184CrossRefPubMedGoogle Scholar
  12. 12.
    Dong Y, Fu C, Guan H et al (2016) Re-irradiation alternatives for recurrent high-grade glioma. Oncol Lett 12(4):2261–2270PubMedPubMedCentralGoogle Scholar
  13. 13.
    Fogh SE, Andrews DW, Glass J, Curran W, Glass C, Champ C et al (2010) Hypofractionated stereotactic radiation therapy: an effective therapy for recurrent high-grade gliomas. J Clin Oncol Off J Am Soc Clin Oncol 28(18):3048–3053CrossRefGoogle Scholar
  14. 14.
    Fokas E, Wacker U, Gross MW, Henzel M, Encheva E, Engenhart-Cabillic R (2009) Hypofractionated stereotactic reirradiation of recurrent glioblastomas: a beneficial treatment option after high-dose radiotherapy? Strahlenther Onkol Organ Dtsch Roentgenges Al 185(4):235–240CrossRefGoogle Scholar
  15. 15.
    Gorlia T, van den Bent MJ, Hegi ME et al (2008) Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3. Lancet Oncol 9(1):29–38CrossRefPubMedGoogle Scholar
  16. 16.
    Grosu AL, Weber WA, Franz M, Stärk S, Piert M, Thamm R et al (2005) Reirradiation of recurrent high-grade gliomas using amino acid PET (SPECT)/CT/MRI image fusion to determine gross tumor volume for stereotactic fractionated radiotherapy. Int J Radiat Oncol Biol Phys 63(2):511–519CrossRefPubMedGoogle Scholar
  17. 17.
    Gutin PH, Iwamoto FM, Beal K, Mohile NA, Karimi S, Hou BL, Lymberis S, Yamada Y, Chang J, Abrey LE (2009) Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas. Int J Radiat Oncol Biol Phys 75:156–163CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Henke G, Paulsen F, Steinbach JP, Ganswindt U, Isijanov H, Kortmann R-D et al Hypofractionated reirradiation for recurrent malignant glioma. Strahlenther Onkol Organ Dtsch Roentgenges Al 185(2):113–119Google Scholar
  19. 19.
    Hudes RS, Corn BW, Werner-Wasik M, Andrews D, Rosenstock J, Thoron L et al (1999) A phase I dose escalation study of hypofractionated stereotactic radiotherapy as salvage therapy for persistent or recurrent malignant glioma. Int J Radiat Oncol Biol Phys 43(2):293–298CrossRefPubMedGoogle Scholar
  20. 20.
    Hundsberger T, Brügge D, Putora PM, Weder P, Weber J, Plasswilm L (2013) Re-irradiation with and without bevacizumab as salvage therapy for recurrent or progressive high-grade gliomas. J Neuro-Oncol 112:133–139CrossRefGoogle Scholar
  21. 21.
    Lederman G, Wronski M, Arbit E, Odaimi M, Wertheim S, Lombardi E et al (2000) Treatment of recurrent glioblastoma multiforme using fractionated stereotactic radiosurgery and concurrent paclitaxel. Am J Clin Oncol 23(2):155–159CrossRefPubMedGoogle Scholar
  22. 22.
    Macdonald DR, Cascino TL, Schold SC Jr et al (1990) Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8:1277–1280CrossRefPubMedGoogle Scholar
  23. 23.
    Mayer R, Sminia P (2008) Reirradiation tolerance of the human brain. Int J Radiat Oncol Biol Phys 70(5):1350–1360CrossRefPubMedGoogle Scholar
  24. 24.
    Minniti G, Armosini M, Salvati G et al (2011) Fractionated stereotactic reirradiation and concurrent temozolomide in patients with recurrent glioblastoma. J Neuro-Oncol 103(3):683–691CrossRefGoogle Scholar
  25. 25.
    Mohammed AM, Osman (2014) Phase II trial of temozolomide and reirradiation using conformal 3D-radiotherapy in recurrent brain gliomas. Ann Transl Med 2(5):44Google Scholar
  26. 26.
    Niyazi M, Ganswindt U, Schwarz SB, Kreth F-W, Tonn J-C, Geisler J et al (2012) Irradiation and bevacizumab in high-grade glioma retreatment settings. Int J Radiat Oncol Biol Phys 82(1):67–76CrossRefPubMedGoogle Scholar
  27. 27.
    Neyns B, Everaert E, Joosens E et al (2004) Temozolomide for the treatment of recurrent glioma: results of a compassionate use program in Belgium. J Clin Oncol 22:abstr 1541CrossRefGoogle Scholar
  28. 28.
    Patel M, Siddiqui F, Jin J-Y, Mikkelsen T, Rosenblum M, Movsas B et al (2009) Salvage reirradiation for recurrent glioblastoma with radiosurgery: radiographic response and improved survival. J Neuro-Oncol 92(2):185–191CrossRefGoogle Scholar
  29. 29.
    Roy S, Lahiri D, Biswas J (2015) Recurrent glioblastoma: where we stand. South Asian J Cancer 4(4):163–173CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Stupp R, Hegi ME, Mason WP et al (2009) European Organisation for Research and Treatment of Cancer Brain Tumour and Radiation Oncology Groups; National Cancer Institute of Canada Clinical Trials Group. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10(5):459–466CrossRefPubMedGoogle Scholar
  31. 31.
    Stupp R, Mason WP, van den Bent MJ et al (2005) European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10):987–996CrossRefPubMedGoogle Scholar
  32. 32.
    Su YW, Chang MC, Chiang MF, Hsieh RK (2005) Treatment-related myelodysplastic syndrome after temozolomide for recurrent high-grade glioma. J Neuro-Oncol 71(3):315–318CrossRefGoogle Scholar
  33. 33.
    van Kampen M, Engenhart-Cabillic R, Debus J, Fuss M, Rhein B, Wannenmacher M (1998) The radiosurgery of glioblastoma multiforme in cases of recurrence. The Heidelberg experiences compared to the literature. Strahlenther Onkol Organ Dtsch Rontgenges Al 174(1):19–24CrossRefGoogle Scholar
  34. 34.
    Veninga T, Langendijk HA, Slotman BJ et al (2001) Reirradiation of primary brain tumours: survival, clinical response and prognostic factors. Radiother Oncol 59:127–137CrossRefPubMedGoogle Scholar
  35. 35.
    Vordermark D, Kölbl O, Ruprecht K, Vince GH, Bratengeier K, Flentje M (2005) Hypofractionated stereotactic re-irradiation: treatment option in recurrent malignant glioma. BMC Cancer 5:55CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Vredenburgh JJ, Desjardins A, Herndon JE II et al (2007) Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 13(4):1253–1259CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2017

Authors and Affiliations

  • Tejinder Kataria
    • 1
  • Deepak Gupta
    • 1
  • Ratika Gupta
    • 1
  • Shikha Goyal
    • 1
  • Shyam Singh Bisht
    • 1
  • Trinanjan Basu
    • 1
  • Ashu Abhishek
    • 1
  • Kushal Narang
    • 1
  • Susovan Banerjee
    • 1
  1. 1.Radiation OncologyMedanta—The MedicityGurgaonIndia

Personalised recommendations